Thomas J Smith

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5980059/publications.pdf

Version: 2024-02-01

247 26,069 papers citations

6471 63 h-index

157

g-index

252 252 252 21037 all docs docs citations times ranked citing authors

#	Article	IF	CITATIONS
1	An Examination of Audit Quality Surrounding Within-Firm Engagement Office Changes. Journal of Accounting, Auditing & Finance, 2024, 39, 255-277.	1.8	1
2	Audit Efficiency and Effectiveness Consequences of Accounting System Homogeneity across Audit Clients: A New Form of Knowledge Spillover?. Accounting Review, 2023, 98, 389-418.	3.2	5
3	Improving Palliative Care and Quality of Life in Pancreatic Cancer Patients. Journal of Palliative Medicine, 2022, 25, 720-727.	1.1	22
4	Effects of an Oncology Nurse-Led, Primary Palliative Care Intervention (CONNECT) on Illness Expectations Among Patients With Advanced Cancer. JCO Oncology Practice, 2022, 18, e504-e515.	2.9	2
5	Improving providers' survival estimates and selection of prognosis―and guidelinesâ€appropriate treatment for patients with symptomatic bone metastases: Development of the Bone Metastases Ensemble Trees for Survival Decision Support Platform. Journal of Evaluation in Clinical Practice, 2022	1.8	2
6	Oncologist Peer Comparisons as a Behavioral Science Strategy to Improve Hospice Utilization. JCO Oncology Practice, 2022, 18, e1122-e1131.	2.9	5
7	Specialty Palliative Care: No Apologies. Journal of Pain and Symptom Management, 2022, , .	1.2	O
8	Hospice Family Caregiver Perceptions of Benefits and Challenges of a Telenovela Educational Intervention. Journal of Palliative Medicine, 2022, 25, 945-951.	1.1	3
9	What Does an Executive Stock Sale Tell the Market? Evidence From Sale Transactions Following Stock Option Exercises. Journal of Accounting, Auditing & Finance, 2021, 36, 613-642.	1.8	O
10	External Validation of the Bone Metastases Ensemble Trees for Survival (BMETS) Machine Learning Model to Predict Survival in Patients With Symptomatic Bone Metastases. JCO Clinical Cancer Informatics, 2021, 5, 304-314.	2.1	7
11	Scrambler therapy for incident pain in bone metastases. Journal of Osteopathic Medicine, 2021, 121, 539-542.	0.8	1
12	Initial Management of Noncastrate Advanced, Recurrent, or Metastatic Prostate Cancer: ASCO Guideline Update. Journal of Clinical Oncology, 2021, 39, 1274-1305.	1.6	67
13	Successful Treatment With Scrambler Therapy for Radial and Femoral Nerve Injuries After Extracorporeal Membrane Oxygenation. Mayo Clinic Proceedings, 2021, 96, 1374-1375.	3.0	1
14	Developing Workshops to Enhance Hope Among Patients With Metastatic Breast Cancer and Oncologists: A Pilot Study. JCO Oncology Practice, 2021, 17, e785-e793.	2.9	11
15	Use of Scrambler Therapy in the Treatment of Amyloidosis Neuropathic Pain. Journal of Palliative Medicine, 2021, 24, 1579-1581.	1.1	2
16	The impact of CIO characteristics on data breaches. International Journal of Accounting Information Systems, 2021, 43, 100532.	5.0	10
17	A Pilot Randomized Sham-Controlled Trial of MC5-A Scrambler Therapy in the Treatment of Chronic Chemotherapy-Induced Peripheral Neuropathy (CIPN). Journal of Palliative Care, 2020, 35, 53-58.	1.0	25
18	Using Patient-Reported Outcomes to Describe the Patient Experience on Phase I Clinical Trials. JNCI Cancer Spectrum, 2020, 4, pkaa067.	2.9	7

#	Article	IF	Citations
19	Aromatase inhibitor therapy in recurrent, estrogen-receptor positive uterine serous carcinoma: A case report. Gynecologic Oncology Reports, 2020, 32, 100555.	0.6	2
20	Treatment of Déjerine–Roussy syndrome pain with scrambler therapy. Pain Management, 2020, 10, 141-145.	1.5	7
21	The Effects of Information Systems Compatibility on Firm Performance following Mergers and Acquisitions. Journal of Information Systems, 2020, 34, 211-233.	1.2	7
22	Accrual Management and the Decision to Sell or Hold Shares Acquired from the Exercise of Employee Stock Options. Journal of Financial Reporting, 2020, 5, 115-134.	1.5	0
23	Do Auditors Price Breach Risk in Their Audit Fees?. Journal of Information Systems, 2019, 33, 177-204.	1.2	46
24	Highâ€Risk Palliative Care Patients' Knowledge and Attitudes about Hereditary Cancer Testing and DNA Banking. Journal of Genetic Counseling, 2018, 27, 834-843.	1.6	6
25	Earnings management strategies to maintain a string of meeting or beating analyst expectations. Advances in Accounting, 2018, 43, 46-55.	1.0	20
26	DOES MANAGERIAL OPPORTUNISM EXPLAIN THE DIFFERENTIAL PRICING OF LEVEL 3 FAIR VALUE ESTIMATES?. Journal of Financial Research, 2018, 41, 253-289.	1.2	9
27	Homing in on the Social: System-Level Influences on Overly Aggressive Treatments at the End of Life. Journal of Pain and Symptom Management, 2018, 55, 282-289.e1.	1.2	29
28	A cluster randomized trial of a primary palliative care intervention (CONNECT) for patients with advanced cancer: Protocol and key design considerations. Contemporary Clinical Trials, 2017, 54, 98-104.	1.8	31
29	Integration of Palliative Care Into Standard Oncology Care: American Society of Clinical Oncology Clinical Practice Guideline Update. Journal of Clinical Oncology, 2017, 35, 96-112.	1.6	1,454
30	Cost analysis of a prospective multi-site cohort study of palliative care consultation teams for adults with advanced cancer: Where do cost-savings come from?. Palliative Medicine, 2017, 31, 378-386.	3.1	96
31	The Relationship between Aggressive Real Earnings Management and Current and Future Audit Fees. Auditing, 2017, 36, 85-107.	1.9	82
32	Implementing Evidence-Based Palliative Care Programs and Policy for Cancer Patients: Epidemiologic and Policy Implications of the 2016 American Society of Clinical Oncology Clinical Practice Guideline Update. Epidemiologic Reviews, 2017, 39, 123-131.	3.5	13
33	End of life care for glioblastoma patients at a large academic cancer center. Journal of Neuro-Oncology, 2017, 134, 75-81.	2.9	19
34	A Single Center Survey of Health-Related Quality of Life among Acute Myeloid Leukemia Survivors in First Complete Remission. Journal of Palliative Medicine, 2017, 20, 1267-1273.	1.1	8
35	A Standard Set of Value-Based Patient-Centered Outcomes for Breast Cancer. JAMA Oncology, 2017, 3, 677.	7.1	167
36	NCCN Guidelines Insights: Palliative Care, Version 2.2017. Journal of the National Comprehensive Cancer Network: JNCCN, 2017, 15, 989-997.	4.9	98

#	Article	IF	CITATIONS
37	Treatment of human immunodeficiency virus-related peripheral neuropathy with Scrambler Therapy: a case report. International Journal of STD and AIDS, 2017, 28, 202-204.	1.1	20
38	A Singular Hope: How the Discussion Around Cancer Surgery Sometimes Fails. Annals of Surgical Oncology, 2017, 24, 31-37.	1.5	25
39	Auditors and net transfers of Level 3 fair-valued financial instruments. Advances in Accounting, 2017, 36, 27-39.	1.0	13
40	AAPT Diagnostic Criteria for Chronic Cancer Pain Conditions. Journal of Pain, 2017, 18, 233-246.	1.4	42
41	Goals-of-care discussions. Journal of Community and Supportive Oncology, 2017, 15, e190-e194.	0.1	11
42	Palliative Care Units Are Really Cost Effective Compared With Usual Care. Journal of Oncology Practice, 2017, 13, 772-773.	2.5	2
43	Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. Journal of Clinical Oncology, 2017, 35, 3484-3515.	1.6	492
44	The TEAM Approach to Improving Oncology Outcomes by Incorporating Palliative Care in Practice. Journal of Oncology Practice, 2017, 13, 557-566.	2.5	40
45	Variations Among Physicians in Hospice Referrals of Patients With Advanced Cancer. Journal of Oncology Practice, 2017, 13, e496-e504.	2.5	23
46	Economic Evaluation of a Hospital-Based Palliative Care Program. Journal of Oncology Practice, 2017, 13, e408-e420.	2.5	21
47	Impact of a New Palliative Care Program on Health System Finances: An Analysis of the Palliative Care Program Inpatient Unit and Consultations at Johns Hopkins Medical Institutions. Journal of Oncology Practice, 2017, 13, e421-e430.	2.5	30
48	Integration of Palliative Care Into Standard Oncology Care: ASCO Clinical Practice Guideline Update Summary. Journal of Oncology Practice, 2017, 13, 119-121.	2.5	172
49	Prospective Cohort Study of Hospitalized Adults With Advanced Cancer: Associations Between Complications, Comorbidity, and Utilization. Journal of Hospital Medicine, 2017, 12, 407-413.	1.4	25
50	Palliative Care and Phase 1 Trials: Intervention to Improve Quality of Life and Provide Education., 2017, 21, 473-479.		11
51	Reining in the Excessive Use of Medical Tests: What Are the Next Steps?. Journal of Clinical Oncology, 2016, 34, 2807-2809.	1.6	0
52	How to Avoid Late Chemotherapy. Journal of Oncology Practice, 2016, 12, 1208-1210.	2.5	7
53	Palliative Care Version 1.2016. Journal of the National Comprehensive Cancer Network: JNCCN, 2016, 14, 82-113.	4.9	57
54	Scrambler Therapy for the management of chronic pain. Supportive Care in Cancer, 2016, 24, 2807-2814.	2,2	64

#	Article	IF	Citations
55	A Pilot Trial to Increase Hospice Enrollment in an Inner City, Academic Emergency Department. Journal of Emergency Medicine, 2016, 51, 106-113.	0.7	14
56	Checkpoint Inhibitors in Lung Cancer Are Not Immune from Cost-Effectiveness Analysis. Journal of Thoracic Oncology, 2016, 11, 1814-1816.	1.1	12
57	Mentoring in Palliative Nursing. Journal of Hospice and Palliative Nursing, 2016, 18, 488-495.	0.9	1
58	Updating the American Society of Clinical Oncology Value Framework: Revisions and Reflections in Response to Comments Received. Journal of Clinical Oncology, 2016, 34, 2925-2934.	1.6	538
59	Moral Distress Amongst American Physician Trainees Regarding Futile Treatments at the End of Life: A Qualitative Study. Journal of General Internal Medicine, 2016, 31, 93-99.	2.6	103
60	Use of inpatient palliative care services in patients with metastatic incurable head and neck cancer. Head and Neck, 2016, 38, 355-363.	2.0	61
61	Bargain Purchase Gains in the Acquisitions of Failed Banks. Journal of Accounting, Auditing & Finance, 2016, 31, 388-412.	1.8	12
62	Fundamentals of Cancer Pain Management. , 2016, , 111-126.		1
63	Palliative Care Teams' Cost-Saving Effect Is Larger For Cancer Patients With Higher Numbers Of Comorbidities. Health Affairs, 2016, 35, 44-53.	5.2	113
64	The Relationship between Board-Level Technology Committees and Reported Security Breaches. Journal of Information Systems, 2016, 30, 79-98.	1.2	94
65	The Current State of Cancer Care in North America. , 2016, , 427-443.		0
66	Real-World Conundrums and Biases in the Use of White Cell Growth Factors. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 36, e524-e527.	3.8	0
67	Recommendations for the Use of White Blood Cell Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update. Journal of Oncology Practice, 2015, 11, 511-513.	2.5	28
68	Scrambler Therapy for Chronic Pain. Clinical Journal of Pain, 2015, 31, 929.	1.9	2
69	North Central Cancer Treatment Group N10C2 (Alliance). Menopause, 2015, 22, 627-632.	2.0	18
70	Early Palliative Care., 2015,, 203-227.		4
71	Trends in the Cost and Use of Targeted Cancer Therapies for the Privately Insured Nonelderly: 2001 to 2011. Journal of Clinical Oncology, 2015, 33, 2190-2196.	1.6	132
72	Influence of Institutional Culture and Policies on Do-Not-Resuscitate Decision Making at the End of Life. JAMA Internal Medicine, 2015, 175, 812.	5.1	95

#	Article	IF	CITATIONS
73	Prospective Cohort Study of Hospital Palliative Care Teams for Inpatients With Advanced Cancer: Earlier Consultation Is Associated With Larger Cost-Saving Effect. Journal of Clinical Oncology, 2015, 33, 2745-2752.	1.6	209
74	Obtaining Helpful Information From the Internet About Prognosis in Advanced Cancer. Journal of Oncology Practice, 2015, 11, 327-331.	2.5	3
75	Preferences for professional versus informal care at end of life amongst African-American drug users with HIV/AIDS. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2015, 27, 218-222.	1.2	7
76	In Reply to Raince and Bloom and Olson. International Journal of Radiation Oncology Biology Physics, 2015, 91, 452-453.	0.8	0
77	Complementary and Integrative Medicine for Older Adults in Palliative Care. Clinics in Geriatric Medicine, 2015, 31, 177-191.	2.6	17
78	American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options. Journal of Clinical Oncology, 2015, 33, 2563-2577.	1.6	783
79	Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update. Journal of Clinical Oncology, 2015, 33, 3199-3212.	1.6	680
80	Patients and Physicians Can Discuss Costs of Cancer Treatment in the Clinic. Journal of Oncology Practice, 2015, 11, 308-312.	2.5	59
81	Geriatrics and Palliative Care: All in the Same Family. Clinics in Geriatric Medicine, 2015, 31, xi-xii.	2.6	1
82	Symptom Management in the Older Adult. Clinics in Geriatric Medicine, 2015, 31, 155-175.	2.6	4
83	Cancer Pain Management. Mayo Clinic Proceedings, 2015, 90, 1428-1439.	3.0	47
84	Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. Journal of Clinical Oncology, 2015, 33, 3488-3515.	1.6	606
85	The Business Case for Palliative Care: Translating Research Into Program Development in the U.S Journal of Pain and Symptom Management, 2015, 50, 741-749.	1.2	57
86	Pilot evaluation of Scrambler therapy for the treatment of chemotherapy-induced peripheral neuropathy. Supportive Care in Cancer, 2015, 23, 943-951.	2.2	81
87	Early integration of palliative care into oncology: evidence, challenges and barriers. Annals of Palliative Medicine, 2015, 4, 122-31.	1.2	51
88	Promoting Palliative Care Worldwide Through International Nursing Education. Journal of Transcultural Nursing, 2014, 25, 410-417.	1.3	21
89	Evidence-Based Palliative Care in the Intensive Care Unit: A Systematic Review of Interventions. Journal of Palliative Medicine, 2014, 17, 219-235.	1.1	223
90	Feasibility of a Palliative Care Intervention for Cancer Patients in Phase I Clinical Trials. Journal of Palliative Medicine, 2014, 17, 1365-1368.	1,1	17

#	Article	IF	CITATIONS
91	Improving the Quality of Cancer Care: Implications for Palliative Care. Journal of Palliative Medicine, 2014, 17, 393-399.	1.1	18
92	AMEN in Challenging Conversations: Bridging the Gaps Between Faith, Hope, and Medicine. Journal of Oncology Practice, 2014, 10, e191-e195.	2.5	35
93	Reply to C.G. Azzoli et al and C. Chouaid et al. Journal of Clinical Oncology, 2014, 32, 3579-3580.	1.6	1
94	Clinic Offering Affordable Radiation Therapy to Increase Access to Care for Patients Enrolled in Hospice. Journal of Oncology Practice, 2014, 10, e390-e395.	2.5	11
95	Using a Question Prompt List As a Communication Aid in Advanced Cancer Care. Journal of Oncology Practice, 2014, 10, e137-e141.	2.5	63
96	A Randomized Trial of the Effectiveness of Topical "ABH Gel―(Ativan®, Benadryl®, Haldol®) vs. Placebo in Cancer Patients With Nausea. Journal of Pain and Symptom Management, 2014, 48, 797-803.	1.2	14
97	Delivering maximum clinical benefit at an affordable price: engaging stakeholders in cancer care. Lancet Oncology, The, 2014, 15, e112-e118.	10.7	80
98	The Growth of Palliative Care in the United States. Annual Review of Public Health, 2014, 35, 459-475.	17.4	187
99	Patterns of Hospice Use in Patients Dying from Hematologic Malignancies. Journal of Palliative Medicine, 2014, 17, 195-199.	1.1	64
100	Patterns of Care Among Patients Receiving Radiation Therapy for Bone Metastases at a Large Academic Institution. International Journal of Radiation Oncology Biology Physics, 2014, 89, 1100-1105.	0.8	45
101	Cost Effectiveness of Crizotinib for Anaplastic Lymphoma Kinase–Positive, Non–Small-Cell Lung Cancer: Who Is Going to Blink at the Cost?. Journal of Clinical Oncology, 2014, 32, 983-985.	1.6	17
102	The ACTTION-American Pain Society Pain Taxonomy (AAPT): An Evidence-Based and Multidimensional Approach to Classifying Chronic Pain Conditions. Journal of Pain, 2014, 15, 241-249.	1.4	159
103	Five Things Physicians and Patients Should Question in Hospice and Palliative Medicine. Journal of Pain and Symptom Management, 2013, 45, 595-605.	1.2	61
104	Radiation Oncologists, Mortality, and Treatment Choices. International Journal of Radiation Oncology Biology Physics, 2013, 87, 437-439.	0.8	5
105	Breast Cancer Follow-Up and Management After Primary Treatment: American Society of Clinical Oncology Clinical Practice Guideline Update. Journal of Clinical Oncology, 2013, 31, 961-965.	1.6	517
106	The Effect of Noisy Fair Value Measures on Bank Capital Adequacy Ratios. Accounting Horizons, 2013, 27, 693-710.	2.1	17
107	Integrating Palliative Care in Oncology. Cancer Journal (Sudbury, Mass), 2013, 19, 373-378.	2.0	52
108	Breast Cancer Surveillance Guidelines. Journal of Oncology Practice, 2013, 9, 65-67.	2.5	14

#	Article	IF	CITATIONS
109	Cost-Effectiveness of Filgrastim and Pegfilgrastim as Primary Prophylaxis Against Febrile Neutropenia in Lymphoma Patients. Journal of the National Cancer Institute, 2013, 105, 1078-1085.	6.3	29
110	Early Specialty Palliative Care â€" Translating Data in Oncology into Practice. New England Journal of Medicine, 2013, 369, 2347-2351.	27.0	231
111	Comparison of Pegfilgrastim Prescribing Practice to National Guidelines at a University Hospital Outpatient Oncology Clinic. Journal of Oncology Practice, 2013, 9, 203-206.	2.5	27
112	A Trial of Scrambler Therapy in the Treatment of Cancer Pain Syndromes and Chronic Chemotherapy-Induced Peripheral Neuropathy. Journal of Pain and Palliative Care Pharmacotherapy, 2013, 27, 359-364.	0.8	65
113	Commentary: "The Lake Wobegon Effect, a Natural Human Tendency to Overestimate One's Capabilities― (Wikipedia). Milbank Quarterly, 2013, 91, 729-737.	4.4	4
114	The "Good Planning Panel― Hastings Center Report, 2013, 43, 30-32.	1.0	4
115	Doing Palliative Care in the Oncology Office. Journal of Oncology Practice, 2013, 9, 84-88.	2.5	15
116	In Chemotherapy for Lung Cancer, Sometimes Less is More. Journal of the National Comprehensive Cancer Network: JNCCN, 2013, 11, 232-235.	4.9	12
117	When Should Radiotherapy Be Considered for Pain Management and What Principles Should Guide the Consideration of Limited-Fraction Versus Full-Dose Radiotherapy?., 2013,, 70-77.		O
118	When Should Epidural or Intrathecal Opioid Infusions and Pumps Be Considered for Pain Management?., 2013,, 93-98.		2
119	When Should Nerve Blocks Be Used for Pain Management?. , 2013, , 99-102.		O
120	When Should Radiopharmaceuticals Be Considered for Pain Management?., 2013,, 78-81.		0
121	A Randomized, Placebo Controlled Trial of Oral Zinc for Chemotherapy-Related Taste and Smell Disorders. Journal of Pain and Palliative Care Pharmacotherapy, 2012, 26, 111-114.	0.8	67
122	Finasteride and Prostate Cancer: A Commentary. Oncologist, 2012, 17, 888-890.	3.7	2
123	Reply to C.T. Stricker et al. Journal of Clinical Oncology, 2012, 30, 1394-1395.	1.6	1
124	Talking with Patients about Dying. New England Journal of Medicine, 2012, 367, 1651-1652.	27.0	50
125	Reply to C.A. Hudis et al. Journal of Clinical Oncology, 2012, 30, 3149-3149.	1.6	O
126	Difficult Cases of Pain and Nonpain Symptoms in Intractable Spinal Infections. American Journal of Hospice and Palliative Medicine, 2012, 29, 493-496.	1.4	1

#	Article	IF	Citations
127	The Impact of Tax Incentives on the Choice to Hold Shares Acquired from Employee Stock Option Exercises. Journal of the American Taxation Association, 2012, 34, 67-91.	1.0	4
128	Wiser Use of Dose-Dense Adjuvant Therapy in Breast Cancer. Journal of Clinical Oncology, 2012, 30, 772-774.	1.6	3
129	American Society of Clinical Oncology Identifies Five Key Opportunities to Improve Care and Reduce Costs: The Top Five List for Oncology. Journal of Clinical Oncology, 2012, 30, 1715-1724.	1.6	538
130	American Society of Clinical Oncology Provisional Clinical Opinion: The Integration of Palliative Care Into Standard Oncology Care. Journal of Clinical Oncology, 2012, 30, 880-887.	1.6	1,171
131	Epoprostenol Use for Pulmonary Arterial Hypertension in the Palliative Care Setting. Journal of Palliative Medicine, 2012, 15, 619-622.	1.1	2
132	Organ Donation after Cardiac Death from Withdrawal of Life Support in Patients with Amyotrophic Lateral Sclerosis. Journal of Palliative Medicine, 2012, 15, 16-19.	1.1	15
133	A Way Forward on the Medically Appropriate Use of White Cell Growth Factors. Journal of Clinical Oncology, 2012, 30, 1584-1587.	1.6	14
134	Reasons Why Physicians Do Not Have Discussions About Poor Prognosis, Why It Matters, and What Can Be Improved. Journal of Clinical Oncology, 2012, 30, 2715-2717.	1.6	256
135	Factors associated with adherence to chemotherapy guidelines in patients with non-small cell lung cancer. Lung Cancer, 2012, 75, 255-260.	2.0	54
136	Survival among non-small cell lung cancer patients with poor performance status after first line chemotherapy. Lung Cancer, 2012, 77, 545-549.	2.0	36
137	Scrambler Therapy May Relieve Chronic Neuropathic Pain More Effectively Than Guideline-Based Drug Management: Results of a Pilot, Randomized, Controlled Trial. Journal of Pain and Symptom Management, 2012, 43, 87-95.	1.2	98
138	ABH Gel Is Not Absorbed From the Skin of Normal Volunteers. Journal of Pain and Symptom Management, 2012, 43, 961-966.	1.2	26
139	A Case of Inaccurate Prognostication After the ARCTIC Protocol. Journal of Pain and Symptom Management, 2012, 43, 1120-1125.	1.2	6
140	A Pilot Trial of Decision Aids to Give Truthful Prognostic and Treatment Information to Chemotherapy Patients with Advanced Cancer. The Journal of Supportive Oncology, 2011, 9, 79-86.	2.3	94
141	Guiding Patients Facing Decisions about "Futile―Chemotherapy. The Journal of Supportive Oncology, 2011, 9, 184-187.	2.3	5
142	Providing Pain and Palliative Care Education Internationally. The Journal of Supportive Oncology, 2011, 9, 129-133.	2.3	9
143	Advancing Palliative Care in Kenya. Cancer Nursing, 2011, 34, E10-E13.	1.5	13
144	Will Patients Want Hospice or Palliative Care if They Do Not Know What It Is?. Journal of Hospice and Palliative Nursing, 2011, 13, 41-46.	0.9	27

#	Article	IF	CITATIONS
145	A pilot phase II trial of magnesium supplements to reduce menopausal hot flashes in breast cancer patients. Supportive Care in Cancer, 2011, 19, 859-863.	2.2	27
146	Using claimsâ€based measures to predict performance status score in patients with lung cancer. Cancer, 2011, 117, 1038-1048.	4.1	43
147	The Shortage of Essential Chemotherapy Drugs in the United States. New England Journal of Medicine, 2011, 365, 1653-1655.	27.0	113
148	Dexmedetomidine as an Adjuvant Analgesic for Intractable Cancer Pain. Journal of Palliative Medicine, 2011, 14, 371-373.	1.1	38
149	2011 Focused Update of 2009 American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non–Small-Cell Lung Cancer. Journal of Clinical Oncology, 2011, 29, 3825-3831.	1.6	259
150	American Society of Clinical Oncology Statement: Toward Individualized Care for Patients With Advanced Cancer. Journal of Clinical Oncology, 2011, 29, 755-760.	1.6	455
151	Is It Time for (Survivorship Care) Plan B?. Journal of Clinical Oncology, 2011, 29, 4740-4742.	1.6	53
152	Physicians' Current Practices and Opportunities for DNA Banking of Dying Patients With Cancer. Journal of Oncology Practice, 2011, 7, 183-187.	2.5	20
153	Genetic Screening and DNA Banking at the End of Life #206. Journal of Palliative Medicine, 2011, 14, 656-657.	1.1	5
154	Bending the Cost Curve in Cancer Care. New England Journal of Medicine, 2011, 364, 2060-2065.	27.0	358
154 155	Bending the Cost Curve in Cancer Care. New England Journal of Medicine, 2011, 364, 2060-2065. Palliative Chemotherapy. Cancer Journal (Sudbury, Mass), 2010, 16, 467-472.	27.0	358
155	Palliative Chemotherapy. Cancer Journal (Sudbury, Mass), 2010, 16, 467-472. Exploring Hereditary Cancer Among Dying Cancer Patients—A Cross-Sectional Study of Hereditary Risk	2.0	13
155 156	Palliative Chemotherapy. Cancer Journal (Sudbury, Mass), 2010, 16, 467-472. Exploring Hereditary Cancer Among Dying Cancer Patients—A Cross-Sectional Study of Hereditary Risk and Perceived Awareness of DNA Testing and Banking. Journal of Genetic Counseling, 2010, 19, 497-525. Pilot Trial of a Patient-Specific Cutaneous Electrostimulation Device (MC5-A Calmare®) for Chemotherapy-Induced Peripheral Neuropathy. Journal of Pain and Symptom Management, 2010, 40,	2.0	13
155 156 157	Palliative Chemotherapy. Cancer Journal (Sudbury, Mass), 2010, 16, 467-472. Exploring Hereditary Cancer Among Dying Cancer Patientsâ€"A Cross-Sectional Study of Hereditary Risk and Perceived Awareness of DNA Testing and Banking. Journal of Genetic Counseling, 2010, 19, 497-525. Pilot Trial of a Patient-Specific Cutaneous Electrostimulation Device (MC5-A Calmare®) for Chemotherapy-Induced Peripheral Neuropathy. Journal of Pain and Symptom Management, 2010, 40, 883-891. Palliative Use of Aminocaproic Acid to Control Upper Gastrointestinal Bleeding. Journal of Pain and	2.0 1.6 1.2	13 18 95
155 156 157	Palliative Chemotherapy. Cancer Journal (Sudbury, Mass), 2010, 16, 467-472. Exploring Hereditary Cancer Among Dying Cancer Patientsâ€"A Cross-Sectional Study of Hereditary Risk and Perceived Awareness of DNA Testing and Banking. Journal of Genetic Counseling, 2010, 19, 497-525. Pilot Trial of a Patient-Specific Cutaneous Electrostimulation Device (MC5-A Calmare®) for Chemotherapy-Induced Peripheral Neuropathy. Journal of Pain and Symptom Management, 2010, 40, 883-891. Palliative Use of Aminocaproic Acid to Control Upper Gastrointestinal Bleeding. Journal of Pain and Symptom Management, 2010, 40, e1-e3. Hospital Mortality Rates: How Is Palliative Care Taken into Account? Journal of Pain and Symptom	2.0 1.6 1.2	13 18 95 2
155 156 157 158	Palliative Chemotherapy. Cancer Journal (Sudbury, Mass), 2010, 16, 467-472. Exploring Hereditary Cancer Among Dying Cancer Patientsâ€"A Cross-Sectional Study of Hereditary Risk and Perceived Awareness of DNA Testing and Banking. Journal of Genetic Counseling, 2010, 19, 497-525. Pilot Trial of a Patient-Specific Cutaneous Electrostimulation Device (MC5-A Calmare®) for Chemotherapy-Induced Peripheral Neuropathy. Journal of Pain and Symptom Management, 2010, 40, 883-891. Palliative Use of Aminocaproic Acid to Control Upper Gastrointestinal Bleeding. Journal of Pain and Symptom Management, 2010, 40, e1-e3. Hospital Mortality Rates: How Is Palliative Care Taken into Account?. Journal of Pain and Symptom Management, 2010, 40, 914-925. Comment on Pegylated Liposomal Doxorubicin Plus Docetaxel in Metastatic Breast Cancer. Journal of	2.0 1.6 1.2 1.2	13 18 95 2 29

#	Article	IF	Citations
163	The "PSOST― Providers' Signout for Scope of Treatment. Journal of Palliative Medicine, 2010, 13, 1055-1058.	1.1	6
164	Clinical and Financial Impact of a Palliative Care Program at a Small Rural Hospital. Journal of Palliative Medicine, 2010, 13, 1339-1343.	1.1	25
165	Concentrating Hospital-Wide Deaths in a Palliative Care Unit: The Effect on Place of Death and System-Wide Mortality. Journal of Palliative Medicine, 2010, 13, 371-374.	1.1	8
166	Palliative Care Consultation and Hospital Length of Stay. Journal of Palliative Medicine, 2010, 13, 761-767.	1.1	48
167	Palliative Care Programs: The Challenges of Growth. Journal of Palliative Medicine, 2010, 13, 1065-1070.	1.1	9
168	Explaining Marginal Benefits to Patients, When "Marginal―Means Additional but Not Necessarily Small. Clinical Cancer Research, 2010, 16, 5981-5986.	7.0	22
169	Paradoxes in Advance Care Planning: The Complex Relationship of Oncology Patients, Their Physicians, and Advance Medical Directives. Journal of Clinical Oncology, 2010, 28, 299-304.	1.6	164
170	Living and Dying in East Africa. Clinical Journal of Oncology Nursing, 2010, 14, 161-166.	0.6	17
171	Barriers to Effective Palliative Care for Low-Income Patients in Late Stages of Cancer: Report of a Study and Strategies for Defining and Conquering the Barriers. Nursing Clinics of North America, 2010, 45, 399-409.	1.5	23
172	Safe Use of Opioids to Manage Pain in Patients With Cirrhosis. Mayo Clinic Proceedings, 2010, 85, 959.	3.0	5
173	Providing palliative care and transitioning patients to hospice: how oncologists and palliative care specialists can work together. Community Oncology, 2010, 7, 136-140.	0.2	3
174	Allocating Cancer-Directed Expenditures: Tensions Between Prevention, Early Detection and Treatment is Unnecessary. Recent Results in Cancer Research, 2010, 188, 1-9.	1.8	1
175	Failure to Accrue to a Study of Nebulized Fentanyl for Dyspnea: Lessons Learned. Journal of Palliative Medicine, 2009, 12, 771-772.	1.1	16
176	Magnesium Supplements for Menopausal Hot Flashes. Journal of Clinical Oncology, 2009, 27, 1151-1152.	1.6	10
177	Efficacy Does Not Necessarily Translate to Cost Effectiveness: A Case Study in the Challenges Associated With 21st-Century Cancer Drug Pricing. Journal of Clinical Oncology, 2009, 27, 2111-2113.	1.6	110
178	Phase I Versus Palliative Care: Striking the Right Balance. Journal of Clinical Oncology, 2009, 27, 307-308.	1.6	17
179	American Society of Clinical Oncology Guidance Statement: The Cost of Cancer Care. Journal of Clinical Oncology, 2009, 27, 3868-3874.	1.6	532
180	Cost and Non-Clinical Outcomes of Palliative Care. Journal of Pain and Symptom Management, 2009, 38, 32-44.	1.2	109

#	Article	IF	Citations
181	Maximal medical therapy and palliative care can work together: When are advanced care measures appropriate?. Journal of Hospital Medicine, 2009, 4, 453-456.	1.4	5
182	American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non–Small-Cell Lung Cancer. Journal of Clinical Oncology, 2009, 27, 6251-6266.	1.6	732
183	Identifying Supportive and Unsupportive Responses of Others. Journal of Psychosocial Oncology, 2008, 26, 81-99.	1.2	15
184	Epidural Screening Before Intrathecal Analgesia. Journal of Pain and Palliative Care Pharmacotherapy, 2008, 22, 69-70.	0.8	2
185	The Role of Chemotherapy at the End of Life. JAMA - Journal of the American Medical Association, 2008, 299, 2667.	7.4	241
186	Intrathoracic Malignant Peripheral Nerve Sheath Tumor in Neurofibromatosis 1. Journal of Clinical Oncology, 2008, 26, 2216-2218.	1.6	13
187	Genetics Assessment at the End of Life: Suggestions for Implementation in Clinic and Future Research. Journal of Palliative Medicine, 2008, 11, 451-458.	1.1	17
188	SPIKE\$: A Six-Step Protocol for Delivering Bad News About the Cost of Medical Care. Journal of Clinical Oncology, 2008, 26, 4200-4204.	1.6	37
189	Reimbursement for Patient and Family Meetings and the Costs of Care at the End of Lifeâ€"Reply. JAMA - Journal of the American Medical Association, 2008, 300, 2119.	7.4	0
190	Palliative Care Consultation in the Process of Organ Donation after Cardiac Death. Journal of Palliative Medicine, 2007, 10, 118-126.	1.1	35
191	Initial Hormonal Management of Androgen-Sensitive Metastatic, Recurrent, or Progressive Prostate Cancer: 2007 Update of an American Society of Clinical Oncology Practice Guideline. Journal of Clinical Oncology, 2007, 25, 1596-1605.	1.6	507
192	Response to "Neutropenic Events in Community Practices Reduced by First and Subsequent Cycle Pegfilgrastim Use― Oncologist, 2007, 12, 1464-1464.	3.7	1
193	Do the Large Benefits Justify the Large Costs of Adjuvant Breast Cancer Trastuzumab?. Journal of Clinical Oncology, 2007, 25, 611-613.	1.6	43
194	Symptom-Oriented Follow-Up of Early Breast Cancer – as Good as Conventional Control and Sparing Resources. Oncology Research and Treatment, 2007, 30, 410-412.	1.2	1
195	Fatal Loeffler's endocarditis due to hypereosinophilic syndrome. American Journal of Hematology, 2007, 82, 920-923.	4.1	28
196	Randomized Trial of Long-Term Follow-Up for Early-Stage Breast Cancer: A Comparison of Family Physician Versus Specialist Care. Journal of Clinical Oncology, 2006, 24, 835-837.	1.6	20
197	2006 Update of Recommendations for the Use of White Blood Cell Growth Factors: An Evidence-Based Clinical Practice Guideline. Journal of Clinical Oncology, 2006, 24, 3187-3205.	1.6	1,530
198	American Society of Clinical Oncology 2006 Update of the Breast Cancer Follow-Up and Management Guidelines in the Adjuvant Setting. Journal of Clinical Oncology, 2006, 24, 5091-5097.	1.6	478

#	Article	IF	Citations
199	Why Do Patients Choose Chemotherapy Near the End of Life? A Review of the Perspective of Those Facing Death From Cancer. Journal of Clinical Oncology, 2006, 24, 3490-3496.	1.6	342
200	A randomized phase III study of radiotherapy alone or with 5-fluorouracil and mitomycin-C in patients with locally advanced adenocarcinoma of the pancreas: Eastern Cooperative Oncology Group study E8282. International Journal of Radiation Oncology Biology Physics, 2005, 62, 1345-1350.	0.8	138
201	Use of an implantable drug delivery system for refractory chronic sickle cell pain. American Journal of Hematology, 2005, 78, 153-154.	4.1	17
202	The American Society of Clinical Oncology Recommended Breast Cancer Surveillance Guidelines Can Be Done in a Routine Office Visit. Journal of Clinical Oncology, 2005, 23, 6807-6807.	1.6	11
203	Implantable Drug Delivery Systems (IDDS) After Failure of Comprehensive Medical Management (CMM) Can Palliate Symptoms in the Most Refractory Cancer Pain Patients. Journal of Palliative Medicine, 2005, 8, 736-742.	1.1	55
204	American Society of Clinical Oncology Recommendations for the Initial Hormonal Management of Androgen-Sensitive Metastatic, Recurrent, or Progressive Prostate Cancer. Journal of Clinical Oncology, 2004, 22, 2927-2941.	1.6	167
205	Lumpectomy plus Tamoxifen with or without Irradiation in Women 70 Years of Age or Older with Early Breast Cancer. New England Journal of Medicine, 2004, 351, 971-977.	27.0	958
206	Massive hydromorphone dose delivered subcutaneously instead of intrathecally: guidelines for prevention and management of opioid, local anesthetic, and clonidine overdose. Journal of Pain and Symptom Management, 2004, 28, 273-276.	1.2	24
207	American Society of Clinical Oncology Treatment of Unresectable Non–Small-Cell Lung Cancer Guideline: Update 2003. Journal of Clinical Oncology, 2004, 22, 330-353.	1.6	1,306
208	Assessment of Optimal Size and Composition of the U.S. National Registry of Hematopoietic Stem Cell Donors. Transplantation, 2004, 78, 89-95.	1.0	95
209	Evidence-based follow-up of lung cancer patients. Seminars in Oncology, 2003, 30, 361-368.	2.2	24
210	Taking Action on the Volume-Quality Relationship: How Long Can We Hide Our Heads in the Colostomy Bag?. Journal of the National Cancer Institute, 2003, 95, 695-697.	6.3	25
211	A High-Volume Specialist Palliative Care Unit and Team May Reduce In-Hospital End-of-Life Care Costs. Journal of Palliative Medicine, 2003, 6, 699-705.	1.1	224
212	Adding Hospice and Palliative Care Services to the Cancer Center Menu. Journal of Palliative Medicine, 2003, 6, 641-644.	1.1	3
213	Randomized Clinical Trial of an Implantable Drug Delivery System Compared With Comprehensive Medical Management for Refractory Cancer Pain: Impact on Pain, Drug-Related Toxicity, and Survival. Journal of Clinical Oncology, 2002, 20, 4040-4049.	1.6	650
214	Truth or Consequences: What to Do When the Patient Doesn't Want to Know. Journal of Clinical Oncology, 2002, 20, 3035-3037.	1.6	14
215	Nebulized Fentanyl Citrate Improves Patients' Perception of Breathing, Respiratory Rate, and Oxygen Saturation in Dyspnea. Journal of Pain and Symptom Management, 2002, 23, 157-160.	1.2	74
216	Why Academic Divisions of Hematology/Oncology Are in Trouble and Some Suggestions for Resolution. Journal of Clinical Oncology, 2001, 19, 260-264.	1.6	15

#	Article	IF	CITATIONS
217	Ensuring Quality Cancer Care by the Use of Clinical Practice Guidelines and Critical Pathways. Journal of Clinical Oncology, 2001, 19, 2886-2897.	1.6	220
218	Ethics of rural health care. Critical Reviews in Oncology/Hematology, 2001, 40, 131-138.	4.4	21
219	Preventive Gynecologic Surgery for BRCA1/2 Carriers— Information for Decision-Making. Gynecologic Oncology, 2001, 83, 168-170.	1.4	6
220	High- and Low-Dose Interferon Alfa-2b in High-Risk Melanoma: First Analysis of Intergroup Trial E1690/S9111/C9190. Journal of Clinical Oncology, 2000, 18, 2444-2458.	1.6	900
221	Tell It Like It Is. Journal of Clinical Oncology, 2000, 18, 3441-3445.	1.6	31
222	2000 Update of Recommendations for the Use of Hematopoietic Colony-Stimulating Factors: Evidence-Based, Clinical Practice Guidelines. Journal of Clinical Oncology, 2000, 18, 3558-3585.	1.6	761
223	Hospital and Physician Volume or Specialization and Outcomes in Cancer Treatment: Importance in Quality of Cancer Care. Journal of Clinical Oncology, 2000, 18, 2327-2340.	1.6	589
224	2000 Update of American Society of Clinical Oncology Colorectal Cancer Surveillance Guidelines. Journal of Clinical Oncology, 2000, 18, 3586-3588.	1.6	135
225	Future strategies needed for palliative care. Seminars in Radiation Oncology, 2000, 10, 254-261.	2.2	1
226	Use of Hematopoietic Colony-Stimulating Factors: Comparison of the 1994 and 1997 American Society of Clinical Oncology Surveys Regarding ASCO Clinical Practice Guidelines. Journal of Clinical Oncology, 1999, 17, 3676-3681.	1.6	73
227	Accelerated superfractionated radiotherapy for inflammatory breast carcinoma: complete response predicts outcome and allows for breast conservation. International Journal of Radiation Oncology Biology Physics, 1999, 44, 289-296.	0.8	32
228	A Rural Cancer Outreach Program Lowers Patient Care Costs and Benefits Both the Rural Hospitals and Sponsoring Academic Medical Center. Journal of Rural Health, 1999, 15, 157-167.	2.9	27
229	A sociodemographic and economic comparison of breast reconstruction, mastectomy, and conservative surgery. Surgery, 1999, 125, 441-447. Combined chemoradiotherapy vs. radiotherapy alone for early stage squamous cell carcinoma of the	1.9	78
230	esophagus: a study of the eastern cooperative oncology group 11Other participating institutions: Albany Medical College, Albany, NY (CA 06594); Albert Einstein College of Medicine, Bronx, NY (CA) Tj ETQq0 0 C) rgBT /Ove	erlogk 10 Tf 5
231	CO; Downstate Medi. International Journal of Radiation Oncology Biology Physics, 1998, 42, 269-276. Standard follow-up of colorectal cancer patients: Finally, we can make practice guidelines based on evidence. Gastroenterology, 1998, 114, 211-213.	1.3	17
232	The American Society of Clinical Oncology Program to Improve End-of-Life Care. Journal of Palliative Medicine, 1998, 1, 221-230.	1.1	26
233	Telling the Truth About Terminal Cancer. JAMA - Journal of the American Medical Association, 1998, 279, 1746.	7.4	52
234	Economic analysis of the clinical uses of the colony-stimulating factors. Current Opinion in Hematology, 1996, 3, 175-179.	2.5	4

#	Article	lF	CITATIONS
235	Factors that Determine the Treatment for Local and Regional Prostate Cancer. Medical Care, 1996, 34, 152-162.	2.4	98
236	Defining Treatment Aims and End-Points in Older Patients With Cancer. Drugs and Aging, 1995, 6, 351-357.	2.7	3
237	Differences in initial treatment patterns and outcomes of lung cancer in the elderly. Lung Cancer, 1995, 13, 235-252.	2.0	160
238	Ways to Reduce the Cost of Oncology Care Without Compromising the Quality. Cancer Investigation, 1994, 12, 257-265.	1.3	10
239	The interactive videoconference: An effective CME delivery system. Journal of Continuing Education in the Health Professions, 1994, 14, 83-89.	1.3	17
240	Cost-Effective Use of Autologous Bone Marrow Transplantation. Pharmacoeconomics, 1994, 6, 114-126.	3.3	4
241	Assessing the cost effectiveness of adjuvant therapies in early breast cancer using a decision analysis model. Breast Cancer Research and Treatment, 1993, 25, 97-105.	2.5	39
242	Breast conservation therapy for early stage breast carcinoma with outstanding 10-year locoregional control rates: A case for aggressive therapy to the tumor bearing quadrant. International Journal of Radiation Oncology Biology Physics, 1993, 27, 545-552.	0.8	57
243	Principles of Cost Effectiveness Analysis for the Assessment of Current and New Therapies. Stem Cells and Development, 1993, 2, 501-506.	1.0	2
244	Should women with node-negative breast cancer receive adjuvant chemotherapy? — Insights from a decision analysis model. Breast Cancer Research and Treatment, 1992, 23, 17-27.	2.5	14
245	Teaching specialty cancer medicine in rural hospitals: The cancer outreach program as a model. Journal of Cancer Education, 1991, 6, 235-240.	1.3	11
246	Efficacy and Cost Effectiveness of Adjuvant Chemotherapy in Women with Node-Negative Breast Cancer. New England Journal of Medicine, 1991, 324, 160-168.	27.0	234
247	Auditor pricing of abnormal income from sales of available for sale securities: evidence from the banking industry. Accounting and Business Research, 0, , 1-35.	1.8	О